Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi Stock

Equities

GENIL

TREGENL00024

Pharmaceuticals

Market Closed - Borsa Istanbul 11:08:00 2024-06-10 am EDT 5-day change 1st Jan Change
63.45 TRY -1.09% Intraday chart for Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi +6.28% +35.35%
Sales 2022 5.45B 168M Sales 2023 8.15B 252M Capitalization 14.06B 434M
Net income 2022 1.08B 33.35M Net income 2023 455M 14.05M EV / Sales 2022 2.76 x
Net cash position 2022 494M 15.26M Net Debt 2023 594M 18.34M EV / Sales 2023 1.8 x
P/E ratio 2022
14.4 x
P/E ratio 2023
30.9 x
Employees 622
Yield 2022
2.15%
Yield 2023
-
Free-Float 25.82%
More Fundamentals * Assessed data
Dynamic Chart
Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi(IBSE:GENIL) added to FTSE All-World Index CI
Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi(IBSE:GENIL) added to S&P Global BMI Index CI
RS Research announced that it has received TRY 12 million in funding from Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi, One Life Ventures GmbH, and other investor CI
Galventa announced that it has received €0.696 million in funding from Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi CI
More news
1 day-1.09%
1 week+6.28%
Current month+4.96%
1 month+11.12%
3 months-16.35%
6 months+19.15%
Current year+35.35%
More quotes
1 week
59.80
Extreme 59.8
64.70
1 month
55.15
Extreme 55.15
66.50
Current year
44.78
Extreme 44.78
84.50
1 year
35.94
Extreme 35.94
84.50
3 years
11.82
Extreme 11.82
84.50
5 years
11.82
Extreme 11.82
84.50
10 years
11.82
Extreme 11.82
84.50
More quotes
Managers TitleAgeSince
Chief Tech/Sci/R&D Officer - 23-06-30
Investor Relations Contact - 21-08-31
Sales & Marketing - 10-07-31
Members of the board TitleAgeSince
Chairman - -
Director/Board Member - -
Director/Board Member - -
More insiders
Date Price Change Volume
24-06-10 63.45 -1.09% 1,218,216
24-06-07 64.15 +2.80% 1,794,661
24-06-06 62.4 +2.13% 1,517,172
24-06-05 61.1 -0.65% 2,267,405
24-06-04 61.5 +3.02% 1,812,000

Delayed Quote Borsa Istanbul, June 10, 2024 at 11:08 am EDT

More quotes
Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS is a Turkey-based company, which engages in manufacturing of pharmaceuticals and other health products. The Company operates in the fields of manufacturing all kinds of pharmaceuticals for human use and health products, trading, import and export. Gen Ilac manufactures products used in the treatment of rare diseases and disorders in neurology, endocrinology, nephrology, oncology, hematology and pediatric branches. The Company has approximately 500 employees working in its production facilities on a closed area of 15,000 square meters, established on an area of approximately 43,000 square meters in Ankara ASO 2nd and 3rd Organized Industrial Zone. Entity has 5 offices abroad: Germany, Russia, Kazakhstan, Uzbekistan and Azerbaijan.
More about the company